Astronomers used powerful telescopes to uncover galaxies of every possible shape and size. From nearby spirals like Andromeda to distant systems formed just hundreds of millions of years after the Big ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...

Vertex Pharmaceuticals Incorporated is downgraded from Buy to Hold due to mounting headwinds and pipeline uncertainties. Vertex faces pressure from potential U.S. drug pricing reforms and tariffs, ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

This story appeared in Esquire's About Time newsletter. Get it free into your inbox every Sunday at 8am. Sign up here You can find the Vertex Watch Company tucked among the narrow cobbled streets, ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...

Vertex Pharmaceuticals’VRTX0.29%increase; green up pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...